ftInvstr
NEULANDLAB · Healthcare ₹22610.0 -1.27% Mkt Cap ₹28908 Cr

NEULANDLAB

Healthcare Drug Manufacturers - Specialty & Generic
₹22610.0
-1.27% today · 30d +4.68%
as of 2026-09-04
Price · Daily Candles
“Neuland Labs: Profit Soars 664% in a Quarter, but Valuations Remain Stretched.”
Neuland Laboratories demonstrated significant quarterly growth, with net profit surging 664.85% YoY to ₹213 Cr and revenue up 136.4% YoY to ₹776 Cr in Q4 2026. However, its TTM PE of 65.34 and PB of 12.69 indicate a stretched valuation compared to historical norms.
BULL CASE
+Quarterly net profit saw an exceptional 664.85% YoY increase to ₹213 Cr in Q4 2026.
+Quarterly revenue grew by 136.4% YoY to ₹776 Cr, alongside a 23.11 percentage point increase in OPM.
+FII holding increased by 0.62 percentage points and DII holding increased by 0.67 percentage points QoQ to 21.08% and 16.51% respectively.
+Annual net profit grew by 39.94% YoY to ₹364 Cr for FY26.
BEAR CASE
The stock trades at a TTM PE of 65.34 and a PB of 12.69, suggesting a high valuation.
ML predictions for Free Cash Flow (FCF) indicate a 'weak' rank, with fcf_1y_stable_7y at 0.0.
The company is currently free-cash-flow negative, with a current FCF of -₹43 Cr.
⟳ What Changed
₹ Latest Earnings · Q ending 2026-06-30
REVENUE
₹642 Cr
+119.15% YoY
NET PROFIT
₹148 Cr
+962.4% YoY
OPM
35.59%
+21.51pp YoY
EPS
₹115.1
PE 65.34
Intrinsic value · DCF: N/A — Company is currently free-cash-flow negative (-0.2% of mktcap). DCF assumes a going concern generating positive cash flow; a meaningful intrinsic value can only be computed once FCF turns positive. Use the Strategy Fit and ML sections instead.
◇ Sector Position
Neuland Laboratories, with a PE of 65.34 and a ROCE of 27.0%, trades at a higher PE than peers like Sun Pharma (42.52) and Cipla (33.96), but comparable to Divi's Lab (77.62).
PEERPEROCE %
NEULANDLAB65.3427.0
SUNPHARMA42.5222.46
DIVISLAB77.6221.47
CIPLA33.9618.37
+ 2 more peers — sign in to view
ML Forward Growth Predictions 🔒

9 ML-predicted forward-growth ranks across sales, EBIT, and FCF.

Sign up freeSign in
75
SCORE / 100
Overall
6-axis composite of the sections below.
Performance STRONG 100
Valuation STRETCHED 20
Growth STRONG 77
Profitability HIGH 92
Technicals STRONG 70
Risk LOW 90
Key Stats
TTM PE
65.34
P/B
12.69
52W HIGH
₹23881.0
OFF HIGH
-5.32%
DIV YIELD
0.18%
MKT CAP
₹28908 Cr
◉ Active Signals
MACDNeutral-227.6301
RSI(14)Neutral54.54
Street Consensus
4 analysts
₹21222.0
mean target
Low ₹20550.0Now ₹22610.0High ₹22913.0
⧉ Strategy Fit 🔒

See which of ftInvstr's 50+ strategies hold NEULANDLAB and at what entry.

Sign up freeSign in